Broad spectrum antibiotic-degrading metallo-β-lactamases are phylogenetically diverse

作     者：Marcelo Monteiro Pedroso David W.Waite Okke Melse Liam Wilson Natasa Mitic Ross P.McGeary Iris Antes Luke W.Guddat Philip Hugenholtz Gerhard Schenk Marcelo Monteiro Pedroso;David W.Waite;Okke Melse;Liam Wilson;Nata(s)a Miti(c);Ross P.McGeary;Iris Antes;Luke W.Guddat;Philip Hugenholtz;Gerhard Schenk

作者机构：School of Chemistry and Molecular BiosciencesThe University of QueenslandSt.LuciaQLDBrisbane 4072Australia Australian Centre for EcogenomicsThe University of QueenslandSt.LuciaQLDBrisbane 4072Australia Center for Integrated Protein Science Munich at the TUM School of Life SciencesTechnische Universit(a)t München85354 FreisingGermany Department of ChemistryMaynooth UniversityMaynoothCo.KildareIreland 

出 版 物：《Protein & Cell》 (蛋白质与细胞（英文版）)

年 卷 期：2020年第11卷第8期

页      面：613-617页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 10[医学] 

基　　金：supported by Project Grants from the NH&MRC 澳大利亚研究理事会(ARC)资助 a Future Fellowship Laureate Fellowship supported by a Science Foundation Ireland-President of Ireland Young Researcher Award(SFI-PIYRA) IA and OM were supported by the Deutsche Forschungsgemeinschaft (SFB 749,project C08 and CIPSM) 

主　　题：hydroxide metallo spectrum 

摘      要：Dear Editor, Antibiotic resistance has emerged as a major threat to global health;multi-drug resistant bacteria already kill more patients in the United States each year than HIV/AIDS, Parkinson s disease, emphysema and homicide combined (Laxminarayan et al., 2013).Among the most effective bacterial resistance mechanisms are β-lactamases, a family of enzymes that are divided into four distinct *** A, C and D (serine-β-lactamases, SBLs) use a catalytic site serine residue to initiate inactivation of the antibiotic, while Class B (metallo-β-lactamases, MBLs) relies on a Zn2+-activated hydroxide (Walsh et al., 2005;Bush and Jacoby,2010;Mitic et al., 2014;Lisa et al., 2017).Clinically relevant inhibitors of Class C and D SBLs are available and in use (e.g., clavulanic acid (CA), Drawz et al., 2010), but for MBLs the search for such inhibitors has remained challenging (McGeary et al., 2017).